NCT00964405View on ClinicalTrials.gov

Phase I Study of GSK233705 in Healthy Japanese Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

September 20, 2008

Primary Completion Date

December 20, 2008

Study Completion Date

December 20, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK233705

Inhaled Long acting muscarinic receptor antagonist

DRUG

Placebo

Matching placebo

Trial Locations (1)

812-0025

GSK Investigational Site, Fukuoka

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00964405 - Phase I Study of GSK233705 in Healthy Japanese Male Subjects | Biotech Hunter | Biotech Hunter